论文部分内容阅读
目的探讨普米克令舒联合博利康尼氧气驱动雾化吸入治疗小儿毛细支气管炎的临床效果。方法 100例小儿毛细支气管炎患儿随机分为观察组与参考组,各50例,参考组在常规治疗的基础上接受博利康尼氧气驱动雾化吸入治疗,观察组同时接受普米克令舒治疗,观察两组患儿临床症状消失时间、治疗总有效率、血氧饱和度改善情况及患儿治疗期间不良反应发生情况。结果观察组咳嗽、咳痰、喘息等症状消失时间明显短于参考组(P<0.05);观察组治疗总有效率明显大于参考组(P<0.05);观察组血氧饱和度治疗后改善情况明显优于参考组(P<0.05),两组患儿治疗期间均未出现不良反应(P>0.05)。结论普米克令舒联合博利康尼氧气驱动雾化吸入治疗小儿毛细支气管炎能够快速缓解临床症状,改善机体氧情况,效果显著。
Objective To investigate the clinical effect of Pulmicort respules combiblipanib aerosol inhalation on pediatric bronchiolitis. Methods 100 cases of children with bronchiolitis were randomly divided into observation group and reference group, 50 cases in each group. The reference group was treated with inhalation of aerosolized inhalation of vicar based on routine therapy. The observation group received Pulmicort resp. The disappearance of clinical symptoms, the total effective rate of treatment, the improvement of oxygen saturation and the incidence of adverse reactions in children during the treatment were observed. Results The disappearance time of cough, expectoration and wheezing in the observation group was significantly shorter than that in the reference group (P <0.05). The total effective rate in the observation group was significantly greater than that in the reference group (P <0.05) (P <0.05). No adverse reaction was found in both groups during treatment (P> 0.05). Conclusions Pulmicort respules combiblipanib aerosol-driven aerosol inhalation therapy for children with bronchiolitis can quickly relieve clinical symptoms and improve the body oxygen situation, the effect is significant.